Biote Corp BTMD.OQ BTMD.O is expected to show a fall in quarterly revenue when it reports results on November 5 for the period ending September 30 2025
The Irving Texas-based company is expected to report a 7.1% decrease in revenue to $47.757 million from $51.38 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
LSEG's mean analyst estimate for Biote Corp is for earnings of 5 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Biote Corp is $5.46, about 47.4% above its last closing price of $2.87
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | 0.06 | 0.06 | 0.18 | Beat | 184.2 |
Mar. 31 2025 | 0.06 | 0.07 | 0.37 | Beat | 469.2 |
Dec. 31 2024 | 0.10 | 0.10 | 0.10 | Met | 0 |
Sep. 30 2024 | 0.08 | 0.09 | 0.33 | Beat | 266.7 |
Jun. 30 2024 | 0.08 | 0.09 | -0.15 | Missed | -273.1 |
Mar. 31 2024 | 0.03 | 0.03 | -0.06 | Missed | -280 |
Dec. 31 2023 | 0.08 | 0.08 | 0.18 | Beat | 134.8 |
Sep. 30 2023 | 0.08 | 0.08 | 0.24 | Beat | 220 |
This summary was machine generated November 3 at 21:04 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments